InflaRx

C5a plays a key role in chronic inflammation by skewing T-cell responses toward pro-inflammatory activity, worsening tissue damage.

The complement system enhances immune responses by clearing microbes, promoting inflammation, and attacking pathogens via the membrane attack complex.

IFX002 is a preclinical anti-C5a antibody with improved humanization and pharmacokinetics, positioned as a follow-up to vilobelimab.

Izicopan is an oral, low-molecular-weight drug targeting C5aR with high affinity, addressing complement-mediated inflammatory conditions.

Authors: Rui Liu, Ophelia Chen, Zhongli Xu, Wantanee Phuapradit, Yazhong Pei, Maria Habel, Niels Riedemann, Renfeng Guo

InflaRx Corporate Presentation August 2026

InflaRx appointed Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development in October 2026.

InflaRx develops anti-inflammatory medicines in Jena, Germany, with a focus on global research and team collaboration.

Dr. Gabriela Alperovich previously led clinical development programs at CSL Vifor, AbbVie, and Bristol-Myers Squibb over 20 years.

Prof. Niels Riedemann founded InflaRx in 2007 and has served as its CEO since inception, leading financing rounds and the company’s 2017 Nasdaq IPO.

InflaRx GmbH was founded in Jena, Germany, in 2007, collaborating closely with Jena University Medical Center for acute care expertise.

InflaRx supports making GOHIBIC available under its FDA emergency use authorization for patients in critical need.

InflaRx focuses on developing anti-C5a and C5aR inhibitors for life-threatening or debilitating inflammatory diseases with high unmet medical need.

1. Name and address of the data controller

Information on the Host of this Internet Web Site